CSIMarket
 
Therapeuticsmd Inc  (NASDAQ: TXMD)
Other Ticker:  
 
 
Price: $1.0100 $-0.01 -0.980%
Day's High: $1.04 Week Perf: 2.02 %
Day's Low: $ 1.00 30 Day Perf: -9.01 %
Volume (M): 22 52 Wk High: $ 2.75
Volume (M$): $ 23 52 Wk Avg: $1.74
Open: $1.00 52 Wk Low: $0.70



 Market Capitalization (Millions $) 12
 Shares Outstanding (Millions) 12
 Employees 142
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) 40
 Capital Exp. (TTM) (Millions $) 0

Therapeuticsmd Inc
TherapeuticsMD Inc is a pharmaceutical company based in Boca Raton, Florida. The company focuses on developing and commercializing innovative products for women's health. Their mission is to improve the lives of women at all stages through life with high-quality, innovative and effective products.

TherapeuticsMD is known for their prescription hormone therapy products such as BIJUVA, which is a combination of estradiol and progesterone designed to treat moderate to severe vasomotor symptoms of menopause. It is the first and only FDA-approved hormone therapy that combines bio-identical estradiol and progesterone in a single, oral capsule dose.

Another hormone therapy product from TherapeuticsMD is IMVEXXY, which is an ultra-low dose vaginal estradiol product designed to help women with moderate to severe painful sex due to menopause. The company also offers a line of vitamins and supplements to support women's health.

In addition to their hormone therapy products, TherapeuticsMD also has a research and development team that is dedicated to discovering and developing new products aimed at treating different women's health conditions. Their team of experts is constantly working on ways to improve women's health through innovative and effective products.

TherapeuticsMD Inc has also made notable progress in their commitment to sustainability, as shown through their recently released Sustainability Report. The report highlights their initiatives in resource reduction, environmental stewardship, and social responsibility.

Overall, TherapeuticsMD Inc is a company that is dedicated to improving women's health through innovative and effective products. With a strong focus on research and development, the company is poised to continue growing and expanding their product offerings in the women's health space.


   Company Address: 951 Yamato Road Boca Raton 33431 FL
   Company Phone Number: 961-1900   Stock Exchange / Ticker: NASDAQ TXMD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.54%    
ABT   -0.76%    
BMY   -7.1%    
JNJ        0.1% 
MRK   -4.03%    
PFE   -2.53%    
• View Complete Report
   



Business Update

An In-depth Review of TherapeuticsMD's Financial Performance in Q1 2024: A Comparative Analysis with Competitors

Published Mon, May 13 2024 5:29 AM UTC

TherapeuticsMD, Inc., a company that notably owns the rights to pharmaceutical royalties (NASDAQ: TXMD), has recently announced their first quarter financial results for the fiscal year 2024. As a respected journal in the field of scientific inquiry and pharmaceutical advancements, we deem it crucial to conduct an extensive review of this eminently influential industry playe...

Business Update

TherapeuticsMD Faces Financial Challenges and Net Loss in First Quarter 2024: A Closer Look at the Pharmaceutical Royalties Company's Performance

Published Sun, May 12 2024 4:45 AM UTC

TherapeuticsMD Reports First Quarter 2024 Financial Results with Net Loss from Continuing OperationsTherapeuticsMD, Inc. (TherapeuticsMD or the Company) (NASDAQ: TXMD) recently released its financial results for the first quarter ending March 31, 2024. The company reported a net loss from continuing operations of $0.8 million, or $0.07 per basic and diluted common share, com...

Business Update

TherapeuticsMD Inc. Skyrockets in Q1 2024, Cementing Its Position as a Leading Pharmaceutical Royalty Holder

Published Sat, May 11 2024 4:24 AM UTC

TherapeuticsMD Inc. Reports Steady Financial Growth in the First Quarter of 2024In an impressive display of financial stability, TherapeuticsMD Inc. (NASDAQ: TXMD) has announced its first quarter 2024 financial results, showcasing a substantial improvement compared to the previous year. As a leading company that holds rights to pharmaceutical royalties, TherapeuticsMD exhibi...

Business Update

TherapeuticsMD in Q1 2024: Navigating Financial Crossroads Amid Competitive Healthcare Market

Published Fri, May 10 2024 8:47 PM UTC

As the first quarter of 2024 concludes, TherapeuticsMD, Inc. (NASDAQ: TXMD), a healthcare-focused company specialising in securing royalties for pharmaceutical products, has made considerable strides towards achieving its financial goals. However, an insightful look into the specifics reveals a mix of wins and losses, suggesting that the journey ahead may still have a few hu...

Therapeuticsmd Inc

TherapeuticsMD Inc Shines Brightly During the Entirety of Q3 2023!

TherapeuticsMD Inc (NASDAQ: TXMD) recently reported its financial results for the third quarter of 2023, showing losses of $0.32 per share. This is a significant improvement from the same quarter last year when the losses were $3.13 per share. In the prior reporting season, the company incurred losses of $0.24 per share.
Furthermore, the net shortfall in the third quarter of 2023 amounted to $3.378 million, a considerable decrease from the deficit of $28.965 million reported in the same quarter the previous year. These positive financial results indicate that TherapeuticsMD Inc is making progress in its transition into a royalty-based business.
Marlan D. Walker, the Chief Executive Officer of TherapeuticsMD, emphasized the company's commitment to cost control in order to maximize the value of its royalty assets. This strategy seems to be yielding positive outcomes, as evidenced by the improved financial performance.
The market also responded positively to TherapeuticsMD Inc's recent performance, as its shares gained 18% over the past week. Compared to the previous year, the shares have gone up by an impressive 56.78%. Additionally, the shares currently trade 21% above their 52-week low.







Therapeuticsmd Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com